NEO2734

SKU: orb1298737

Description

NEO2734 is a potent dual inhibitor of the p300/CBP and BET bromodomain families, exhibiting IC50 values below 30 nM for both targets. This orally bioavailable small molecule is a valuable chemical probe for epigenetic research in oncology, enabling mechanistic studies in both cellular and animal models of cancer.

Research Area

Epigenetics & Chromatin

Key Properties

• CAS Number: 2081072-29-7
• MW: 435.44
• Purity: >99.99% (May vary between batches)
• Formula: C₂₂H₂₄F₃N₃O₃
• SMILES: Cc1cc(cn(C)c1=O)-c1ccc2nc(C3CCOCC3)n(CCOC(F)(F)F)c2c1
• Target: Histone Acetyltransferase,Epigenetic Reader Domain
• Solubility: DMSO:27.5 mg/mL (63.15 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.59 mM)

Bioactivity

• In Vitro:
  NEO2734, a novel dual inhibitor of BET and CBP/p300, is active in both hotspot mutant (F133V) and non-hotspot mutant (Q165P) PCa cells in vitro and in vivo.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

NEO2734, NEO-2734, NEO 2734, inhibit, MYC, Inhibitor, HAT, HATs, Histone Acetyltransferase, HistoneAcetyltransferase, Epigenetic Reader Domain, EpigeneticReaderDomain, EP 31670, EP31670, EP-31670, CBP, BET bromodomain, SPOP, TC-797, p300, p300/CBP, PER-403

Compound Identifiers

PubChem CID

126582741